The truth will set you free
Dave Stack just obliterated Heron on the last warnings call. Said product stinks, is hard to use and causes infections. May as well have said it causes early death or that he’s the real father of Barry’s children.
Heron management has no answer. Sad.
Zynrelef contains DMSO which is a sulfur compound has a slight smell but nothing offensive in terms of what a typical OR encounters. My team has not even mentioned it.
Zynrelef is not difficult to work with and only requires 1-2 minutes for application. It is a novel process and a viscous substance but surgeons have no difficulty working with the product and requires no specialized training to administer. On the contrary Exparel requires 120 injections/aspirations for proper instillation in a TKA case which can take 10-15 minutes if done properly. 5-6 cases per day is another hour of OR time lost or an additional patient lost using a product that does not work beyond the spinal or nerve block duration. (waste of $$$.) Any provider using Exparel has not read the literature. Check with the American Society of Anesthesia ( ASA ) and American Academy of Orthopedic Surgeons ( AAOS ) whom both do not recommend Exparel.
Zynrelef has had no reports of infection. Clinical trials showed no difference in infection rate between placebo, bupivacaine, or Zynrelef. Bupivacaine actually exhibits antimicrobial effects. Zynrelef has actually shown antimicrobial effects a study of Zynrelef in agar showed significant zone of inhibition against staph aureus isolates.
Exparel is losing formulary status at many institutions in favor of Zynrelef. Exparel has not beat standard of care bupivacaine, does not have an extended release profile or label, and adds no benefit in terms of pain control or opioid reduction.
Zynrelef is the first product to demonstrate superiority over standard of care bupivacaine for pain reduction and opioid reduction. AAOS recommends use of local infiltration anesthesia as part of MMA protocol. (Recommends against use of exparel.) Zynrelef was granted and extended release labeling from FDA and fills the significant efficacy gap from 12-72h that current products do not. Controlling pain in the first 72h and reducing opioid consumption decreases LOS, improves functional outcomes, and reduces risk of chronic pain/opioid use.
Zynrelef contains DMSO which is a sulfur compound has a slight smell but nothing offensive in terms of what a typical OR encounters. My team has not even mentioned it.
Zynrelef is not difficult to work with and only requires 1-2 minutes for application. It is a novel process and a viscous substance but surgeons have no difficulty working with the product and requires no specialized training to administer. On the contrary Exparel requires 120 injections/aspirations for proper instillation in a TKA case which can take 10-15 minutes if done properly. 5-6 cases per day is another hour of OR time lost or an additional patient lost using a product that does not work beyond the spinal or nerve block duration. (waste of $$$.) Any provider using Exparel has not read the literature. Check with the American Society of Anesthesia ( ASA ) and American Academy of Orthopedic Surgeons ( AAOS ) whom both do not recommend Exparel.
Zynrelef has had no reports of infection. Clinical trials showed no difference in infection rate between placebo, bupivacaine, or Zynrelef. Bupivacaine actually exhibits antimicrobial effects. Zynrelef has actually shown antimicrobial effects a study of Zynrelef in agar showed significant zone of inhibition against staph aureus isolates.
Exparel is losing formulary status at many institutions in favor of Zynrelef. Exparel has not beat standard of care bupivacaine, does not have an extended release profile or label, and adds no benefit in terms of pain control or opioid reduction.
Zynrelef is the first product to demonstrate superiority over standard of care bupivacaine for pain reduction and opioid reduction. AAOS recommends use of local infiltration anesthesia as part of MMA protocol. (Recommends against use of exparel.) Zynrelef was granted and extended release labeling from FDA and fills the significant efficacy gap from 12-72h that current products do not. Controlling pain in the first 72h and reducing opioid consumption decreases LOS, improves functional outcomes, and reduces risk of chronic pain/opioid use.
In a leadership role we, Pacira, conducted Ad Boards with KOLs at the rate of $2500 a pop. There was no limit on the number of P-value speaker dinners in the budget. We paid unknown grant dollars to physicians and institutions for "research." Speakers were paid $2500-$5000 per speaking engagement.
You data is weak and Heron does not have the cary-through for formulary approvals. Dead in teh water.
You Heron dumbasses (leadership) just need to get out of your own way. The Bad News Bears of pharma.
Thank you Nancy for passing on me. I was paid handsomely throughout the pandemic and my business continues to grow.
In a leadership role we, Pacira, conducted Ad Boards with KOLs at the rate of $2500 a pop. There was no limit on the number of P-value speaker dinners in the budget. We paid unknown grant dollars to physicians and institutions for "research." Speakers were paid $2500-$5000 per speaking engagement.
You data is weak and Heron does not have the cary-through for formulary approvals. Dead in teh water.
You Heron dumbasses (leadership) just need to get out of your own way. The Bad News Bears of pharma.
Thank you Nancy for passing on me. I was paid handsomely throughout the pandemic and my business continues to grow.
Thanks for the update Herron Marketing Department. Second company to launch this product line to the wrong MDs. Anesthesia owns pain control! Stock below $5, enough said.
Stock price has nothing to do with efficacy of Zynrelef. Management surely does but luckily for Heron the zynrelef is outperforming in multiple ongoing trials. It will sell itself with the literature.
You can take PCRX at $70 and I will take HRTX at $5. Check back in 1yr. (HRTX $20+ PCRX down from here. Short term upside as zilretta sales have been decent but their primary revenue gen exparel will start showing declining sales. Already removed from multiple formularies this year. Not just for zynrelef but clinicians are realizing the lack of efficacy and false claims pacira makes.)
Stock price has nothing to do with efficacy of Zynrelef. Management surely does but luckily for Heron the zynrelef is outperforming in multiple ongoing trials. It will sell itself with the literature.
You can take PCRX at $70 and I will take HRTX at $5. Check back in 1yr. (HRTX $20+ PCRX down from here. Short term upside as zilretta sales have been decent but their primary revenue gen exparel will start showing declining sales. Already removed from multiple formularies this year. Not just for zynrelef but clinicians are realizing the lack of efficacy and false claims pacira makes.)
You’re exactly right, the stock price is a reflection of overall company performance and the impression investors have of that and the possibility of a profitable future. That’s why it’s down, the future looks terrible. Z could be the best thing ever but the company and its leadership don’t allow for positive confidence.
So buy it with some of your own money. Quit riding your options and acting like you are some sort of trader. You just don’t have any fans out there on Wall Street so you’ll be right and everyone else will be wrong. Hope for a buy-out.
It honestly appears that Heron “leadership” has never done this before. Seriously. Have they successfully launched a pain product before? Has JP? Shouldn’t be learning g on the job and on shareholders’ dime. Really embarrassing, Heron has better product and being crushed by better team (Pacira) with worse product.
Management matters.
Stupid is as stupid does.
